Drugs / ABX-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07231458 | Oct 2025 → Oct 2026 expected | cancer | Abalos Therapeutics GmbH | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABX-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07231458 ↗ |
| Route | Intravenous | “ABX-001 administered intravenously (IV)” NCT07231458 ↗ |